Landmark Studies Overview

 

For certain topics, trends, and issues that are of particular importance, inVentiv Health Consulting often conducts Landmark Studies™. These are in-depth studies that incorporate a significant amount of primary research, as well as secondary research and analysis. These studies are designed to help industry leaders gain the insights they need for making strategic decisions. 

To learn more about any individual Landmark Study™, please see below.

2017 Dealmakers' Intentions Study
The ninth annual Dealmakers' Intentions 2017 examines what the immediate future holds by surveying dealmakers throughout the industry on their intentions for the rest of the year.

2016 Dealmakers' Intentions Study
Following the best year in history for life sciences dealmaking, the eighth annual Dealmakers' Intentions 2016 examines what the immediate future holds by surveying dealmakers throughout the industry on their intentions for the rest of the year.

2015 Dealmakers' Intentions Study
Following the best year in history for life sciences dealmaking, the seventh annual Dealmakers' Intentions 2015 examines what the immediate future holds by surveying dealmakers throughout the industry on their intentions for the rest of the year.

2014 Dealmakers' Intentions Study
Now in its sixth year, the inVentiv Health Consulting (formerly Campbell Alliance) Dealmakers’ Intentions Study is the only forward-looking measure of dealmaking activity in the pharmaceutical and biotech industries.

2013 Dealmakers' Intentions
Now in its fifth year, Dealmakers’ Intentions is inVentiv Health Consulting's (formerly Campbell Alliance) annual survey of licensing decision makers. It is designed to be forward looking, capturing expectations for deal activity, supply and demand for assets at different stages of development, and approaches to valuation. This whitepaper reviews results of Dealmakers’ Intentions 2013 and presents conclusions that are crucial for C-suite executives, as well as executives responsible for dealmaking strategy and the business development function.

Oncology Index: Maximizing Value in a Changing Paradigm
During the course of the next decade, the oncology market will continue to evolve. To examine the changes that will likely take place over the next 10 years, the inVentiv Health Consulting (formerly Campbell Alliance) second-annual Oncology Index study is focused on the theme of maximizing value in oncology. Specifically, the study addresses the implications for the pharmaceutical industry from the standpoint of identifying value, developing value, and delivering value.

Turning Tides: Trends in Oncology Market Access
The high cost of cancer care presents unique challenges to market access. To better understand these challenges, inVentiv Health Consulting (formerly Campbell Alliance) conducted an in-depth analysis of the issues of greatest concern to the biopharmaceutical industry in the Landmark Study, Turning Tides: Trends in Oncology Market Access.

Medical Affairs Leadership Summit
The annual Medical Affairs (MA) Leadership Summit is a unique opportunity for senior MA executives (vice presidents and above) to discuss key challenges they are facing, share knowledge and best practices, and identify results-oriented solutions.

The 2012 Dealmakers' Intentions Survey
Now in its fourth year, the inVentiv Health Consulting (formerly Campbell Alliance) Dealmakers' Intentions Survey is the only forward-looking measure of deal-making activity in the pharmaceutical and biotech industries. Learn more or download a summary of the results

The 2011 Dealmakers' Intentions Survey
The 2011 Dealmakers' Intentions Survey is the only forward-looking measure of deal-making activity in the pharma and biotech industries. Learn more or download a summary of the results

inVentiv Health Consulting offers world class healthcare consulting services.

Media Contact:

Stephanie Koenig
stephanie.koenig@inventivhealth.com